Trials / Completed
CompletedNCT01334567
Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan
A Rollover Protocol to Provide Subjects From Taiwan Continued Access to Tenofovir Disoproxil Fumarate After Completing Study GS-US-174-0108
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to offer subjects from centers in Taiwan who successfully complete 168 weeks of treatment in study GS US 174-0108 access to treatment with tenofovir DF for up to three additional years (144 weeks). Subjects will be followed per local standard of care. Serious adverse events (SAEs), drug accountability and patient disposition will be recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir DF | Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2011-04-13
- Last updated
- 2014-03-04
Locations
4 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01334567. Inclusion in this directory is not an endorsement.